The CE Mark for the MINItrace Magni enables the in-house supply of fluorine-18 — the molecule used to power GE HealthCare’s Flyrcado, Cerianna and Vizamyl agents — as well as the standards of carbon-11, oxygen-15 and nitrogen-13.
At the same time, the company said its PETtrace cyclotron’s solid target platform will expand into copper-64 production for research use, a metal isotope GE HealthCare said could form the basis for future diagnostic and therapeutic agents in areas such as prostate cancer and HER2-positive breast cancer.